바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.66 No.3
Citation Share

The Effect of Epigallocatechin-3-gallate on HIF-1α and VEGF in Human Lung Cancer Cell Line

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2009, v.66 no.3, pp.178-185
















& (2009). The Effect of Epigallocatechin-3-gallate on HIF-1α and VEGF in Human Lung Cancer Cell Line. Tuberculosis & Respiratory Diseases, 66(3), 178-185.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Epigallocatechin-3-gallate (EGCG) is the major catechin in green tea, and has shown antiproliferative, antiangiogenic, antimetastatic and cell cycle pertubation activity in various tumor models. Hypoxia can be induced because angiogenesis is insufficient for highly proliferating cancer. Hypoxia-inducible factor-1α (HIF-1α) and its downstream target, vascular endothelial growth factor (VEGF), are important for angiogenesis, tumor growth and metastasis. The aim of this study was to determine how hypoxia could cause changes in the cellular phenomena and microenvironment in a non-small cell culture system and to examine the effects of EGCG on a HIF-1α and VEGF in A549 cell line. Methods: A549 cells, a non-small cell lung cancer cell line, were cultured with DMEM and 10% fetal bovine serum. A decrease in oxygen tension was induced using a hypoxia microchamber and a CO2-N2 gas mixture. Gas analysis and a MTT assay were performed. The A549 cells were treated with EGCG (0, 12.5, 25, 50 μmol/L), and then examined by real-time-PCR analysis of HIF-1α, VEGF, and β-actin mRNA. Results: Hypoxia reduced the proliferation of A549 cells from normoxic conditions. EGCG inhibited HIF-1α transcription in A549 cells in a dose-dependent manner. Compared to HIF-1α, VEGF was not inhibited by EGCG. Conclusion: HIF-1α can be inhibited by EGCG. This suggests that targeting HIF-1α with a EGCG treatment may have therapeutic potential in non-small cell lung cancers.

keywords
HIF-1α, VEGF, EGCG, Lung cancer, Hypoxia

Reference

1.

O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36:151-69.

2.

Brown JM. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-70.

3.

Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999;80:1697-707.

4.

Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005; 65:2387-96.

5.

Büchler P, Reber HA, Lavey RS, Tomlinson J, Büchler MW, Friess H, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 2004;120:295-303.

6.

Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004;5:27.

7.

Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006;58:776-84.

8.

Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000;48:545-53.

9.

Swinson DE, O'Byrne KJ. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 2006;7:250-6.

10.

Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-80.

11.

Wang T, Niki T, Goto A, Ota S, Morikawa T, Nakamura Y, et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. Cancer Sci 2007;98:506-11.

12.

Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000;60:2936-41.

13.

Li L, Yu J, Xing L, Ma K, Zhu H, Guo H, et al. Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer. Am J Clin Oncol 2006;29:628-33.

14.

Shin JW, Jeon EJ, Kwak HW, Song JH, Lee YW, Jeong JW, et al. Microenvironments and cellular proliferation affected by oxygen concentration in non-small cell lung cancer cell line. Tuberc Respir Dis 2007;63:242-50.

15.

Kobayashi S, Conforti L, Pun RY, Millhorn DE. Adenosine modulates hypoxia-induced responses in rat PC12 cells via the A2A receptor. J Physiol 1998;508:95-107.

16.

Ziemer LS, Lee WM, Vinogradov SA, Sehgal C, Wilson DF. Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. J Appl Physiol 2005;98:1503-10.

17.

Mairbäurl H, Wodopia R, Eckes S, Schulz S, Bärtsch P. Impairment of cation transport in A549 cells and rat alveolar epithelial cells by hypoxia. Am J Physiol 1997; 273:L797-806.

18.

O'Kelly I, Peers C, Kemp PJ. O2-sensitive K+ channels in neuroepithelial body-derived small cell carcinoma cells of the human lung. Am J Physiol 1998;275:L709-16.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy